Update on Adaptimmune's SURPASS Family of Trials

Update on Adaptimmune's SURPASS Family of TrialsПодробнее

SURPASS-2: investing ADP-A2M4CD8 SPEAR T-cell therapy to treat esophageal and GEJ cancersПодробнее

Adaptimmune Therapeutics kicks off SURPASS clinical trial to target solid tumor cancersПодробнее

SURPASS: evaluating the next-generation of SPEAR T-cell therapyПодробнее

Capacity Building of National Consortium PhD guides dated 20.01.2025.Подробнее

2024 ASF Family Conference - Pharma and Biotech Industry UpdateПодробнее

Jeanine 2 ITD VideoПодробнее

Adaptimmune reports updated SURPASS data at ESMO 2021Подробнее

Next steps for membership structure implementationПодробнее

which phas e result s in 2 d a ughter cells? metaphase prophase telophase cytokinesisПодробнее

Recent FDA Approval of Ribociclib as Upfront TherapyПодробнее

Community Webinar: Updates on DELIVER TrialПодробнее

Family Forum 2024: The Duchenne Registry & Clinical TrialsПодробнее

ACROBiosystems Contribution to Precision MedicineПодробнее

Webinar: INSPIRE DUCHENNE Clinical Trial Update and Study ExpansionПодробнее